Genzyme and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics for Novel MalariaTherapies
Genzyme Corp. and Medicines for malaria Venture (MMV) announced a new collaboration with India’s Advinus Therapeutics Ltd. The collaboration seeks to develop new, improved treatments for specific patient groups most at risk for malaria.
The ongoing MMV/Genzyme partnership also includes The Broad Institute of MIT and Harvard. The team has begun to identify promising lead candidates, coming out of its innovative platform for high-throughput screening of several compound libraries. Among the kinds of compounds to be optimized, with the help of Advinus, are those active against key target enzymes that are essential for the survival of the malaria parasite.
Based in Bangalore, India, Advinus is a TATA-promoted life sciences research and development company with extensive expertise in pharmaceutical R&D. With the complementary skills and experience Advinus brings, the collaboration will focus on identifying new molecules effective at fighting malaria, from early-stage screening to the first steps of preclinical assessment. One important aim is to develop therapies to address the danger of emerging drug resistance that current antimalarial treatments increasingly face.
Other news from the department research and development
